Gender differences in neurological disease

被引:90
作者
Czlonkowska, Anna
Ciesielska, Agnieszka
Gromadzka, Grazyna
Kurkowska-Jastrzebska, Iwona
机构
[1] Inst Psychiat & Neurol, Dept Neurol 2, PL-02957 Warsaw, Poland
[2] Med Univ Warsaw, Dept Expt & Clin Pharmacol, PL-02957 Warsaw, Poland
关键词
estrogen; inflammatory reaction; cytokines; neurological disorders;
D O I
10.1385/ENDO:29:2:243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasing evidence suggests that inflammatory response may be a critical component of different brain pathologies. However, the role played by this reaction is not fully understood. The present findings suggest that neuroinflammtory mediators such as cytokines may be involved in a number of key steps in the pathological cascade of events leading to neuronal injury. This hypothesis is strongly supported by experimental and clinical observations indicating that inhibition of the inflammatory reaction correlates with less neuronal damage. Estrogens are thought to play a role in the sex difference observed in many neurological diseases with inflammatory components including stroke, Alzheimer's and Parkinson's diseases, multiple sclerosis, or amyotrophic lateral sclerosis. Clinical and experimental studies have established estrogen as a neuroprotective hormone in these diseases. However, the exact mechanisms involved in the neuroprotective effects of estrogens are still unclear. It is possible that the beneficial effects of these hormones may be dependent on their inhibitory activity on the inflammatory reaction associated with the above-mentioned brain pathologies. Here, we review the current clinical and experimental evidence with respect to the inflammation-modulating effects of estrogens as one potential explanatory factor for sexual dimorzphism in the prevalence of numerous neurological diseases.
引用
收藏
页码:243 / 256
页数:14
相关论文
共 186 条
[41]   The inflammatory response in cerebral ischemia: Focus on cytokines in stroke patients [J].
De Simoni, MG ;
Milia, P ;
Barba, M ;
De Luigi, A ;
Parnetti, L ;
Gallai, V .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2002, 24 (7-8) :535-542
[42]  
del Zoppo G, 2000, BRAIN PATHOL, V10, P95
[43]   Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe - Data from a multicenter multinational hospital-based registry [J].
Di Carlo, A ;
Lamassa, M ;
Baldereschi, M ;
Pracucci, G ;
Basile, AM ;
Wolfe, CDA ;
Giroud, M ;
Rudd, A ;
Ghetti, A ;
Inzitari, D .
STROKE, 2003, 34 (05) :1114-1119
[44]   Estrogen and brain inflammation: Effects on microglial expression of MHC, costimulatory molecules and cytokines [J].
Dimayuga, FO ;
Reed, JL ;
Carnero, GA ;
Wang, CM ;
Dimayuga, ER ;
Dimayuga, VM ;
Perger, A ;
Wilson, ME ;
Keller, JN ;
Bruce-Keller, AJ .
JOURNAL OF NEUROIMMUNOLOGY, 2005, 161 (1-2) :123-136
[45]  
Dluzen D E, 2000, J Gend Specif Med, V3, P36
[46]  
Dluzen DE, 1996, J NEUROCHEM, V66, P658
[47]   Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice [J].
Dluzen, DE ;
McDermott, JL ;
Liu, BJ .
NEUROTOXICOLOGY AND TERATOLOGY, 1996, 18 (05) :603-606
[48]   The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials [J].
Doraiswamy, PM ;
Bieber, F ;
Kaiser, L ;
Krishnan, KR ;
ReuningScherer, J ;
Gulanski, B .
NEUROLOGY, 1997, 48 (06) :1511-1517
[49]   Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17β-estradiol in apolipoprotein E-deficient mice [J].
Elhage, R ;
Clamens, S ;
Besnard, S ;
Mallat, Z ;
Tedgui, A ;
Arnal, JF ;
Maret, A ;
Bayard, F .
ATHEROSCLEROSIS, 2001, 156 (02) :315-320
[50]   A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury [J].
Fahrig, T ;
Gerlach, I ;
Horváth, E .
MOLECULAR PHARMACOLOGY, 2005, 67 (05) :1544-1555